Heart rate and use of beta-blockers in Mexican stable outpatients with coronary artery disease

被引:5
|
作者
Antonio Alcocer-Gamba, Marco [1 ,2 ,3 ]
Martinez-Sanchez, Carlos [3 ,4 ]
Verdejo-Paris, Juan [3 ,4 ]
Ferrari, Roberto [5 ,6 ,7 ]
Fox, Kim [8 ]
Greenlaw, Nicola [9 ]
Steg Philippe, Gabriel [8 ,10 ,11 ,12 ]
机构
[1] Inst Corazon Queretaro, Queretaro, Mexico
[2] Nacl CLARIFY, Queretaro, Mexico
[3] Soc Mexicana Cardiol, Mexico City, DF, Mexico
[4] Inst Nacl Cardiol Ignacio Chavez, Cd Mexico, Mexico
[5] Univ Hosp Ferrara, Dept Cardiol, Cotignola, Italy
[6] Univ Hosp Ferrara, LTTA Ctr, Cotignola, Italy
[7] ES Hlth Sci Fdn, Maria Cecilia Hosp, GVM Care & Res, Cotignola, Italy
[8] NHLI Imperial Coll, Royal Brompton Hosp, ICMS, London, England
[9] Univ Glasgow, Glasgow, Lanark, Scotland
[10] INSERM, U698, Paris, France
[11] Univ Paris Diderot, Paris, France
[12] Hop Bichat Claude Bernard, AP HP, Paris, France
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2015年 / 85卷 / 04期
关键词
Heart rate; beta-Blockers; Stable coronary artery disease; Mexico;
D O I
10.1016/j.acmx.2015.01.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the use of beta-blockers and to monitor heart rate in Mexican patients with coronary artery disease. Methods: CLARIFY is an outpatients registry with stable CAD. A total of 33,283 patients from 45 countries were enrolled between November 2009 and July 2010 from which 1342 were Mexican patients. Results: The mean HR pulse was 70 bpm (beats per minute). Patients in Mexico were compared with the remaining global CLARIFY population. Patients in Mexico had a higher incidence of acute myocardial infarction and percutaneous coronary intervention, and lower incidence of revascularization surgery compared with the remaining CLARIFY population. More often, Mexican patients presented with diabetes, but less often hypertension and stroke. These patients were split into three mutually exclusive groups of HR <= 60 (N = 263), HR 61-69 (N = 356) and HR >= 70 (N = 722). Patients with elevated HR had a higher incidence of diabetes and higher diastolic blood pressure on average than those with controlled HR. Regarding the use of beta-blockers, they were used in 63.3% of patients, 2.7% showed intolerance or contraindication to treatment to monitor heart rate, and ivabradine was used in 2.3%. Out of approximately 849 patients receiving treatment of beta-blockers, 52.1% had >= 70 bpm HR. Conclusions: In a large proportion of Mexican patients with stable coronary disease the HR remain elevated, >70 bpm, even with the use of beta-blockers; this requires further attention. (C) 2014 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S. A. All rights reserved.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 50 条
  • [41] THE RELATIVE RISK OF INCIDENT CORONARY HEART-DISEASE ASSOCIATED WITH RECENTLY STOPPING THE USE OF BETA-BLOCKERS
    PSATY, BM
    KOEPSELL, TD
    WAGNER, EH
    LOGERFO, JP
    INUI, TS
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (12): : 1653 - 1657
  • [42] BETA-BLOCKERS IN ISCHEMIC-HEART-DISEASE
    WILHELMSSON, C
    VEDIN, A
    AMERICAN JOURNAL OF CARDIOLOGY, 1983, 52 (02): : A108 - A112
  • [43] Mortality and morbidity with beta-blockers in very elderly heart failure outpatients
    Borelli, G.
    Rondinini, L.
    Coceani, M.
    Barison, A.
    Morelli, I.
    Conte, L.
    Mariotti, R.
    EUROPEAN HEART JOURNAL, 2007, 28 : 51 - 51
  • [44] Persistence with beta-blockers in coronary heart disease patients in UK primary care
    Setakis, E.
    Morley, C.
    Cockle, S.
    Van Staa, T. P.
    Kassianos, G.
    EUROPEAN HEART JOURNAL, 2009, 30 : 303 - 304
  • [45] Beta-Blockers and Cardiovascular Outcomes in Acute Heart Failure with a History of Coronary Artery Disease and an Ejection Fraction ≥ 40%
    Khalil, Charbel Abi
    Sulaiman, Kadhim
    Asaad, Nidal
    AlHabib, Khalid F.
    Alsheikh-Ali, Alawi
    Jameesh, Mohammed
    Al-Jarallah, Mohammed
    Bulbanat, Bassam
    AlMahmeed, Wael
    Ridha, Mustafa
    Bazargani, Nooshin
    Amin, Haitham
    Al-Motarreb, Ahmed
    AlFaleh, Husam
    Panduranga, Prashanth
    Mahfoud, Ziyad
    Al Suwaidi, Jassim
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (06) : 644 - 651
  • [46] CORONARY-PRONE BEHAVIOR PATTERN AND CORONARY HEART-DISEASE - IMPLICATIONS FOR THE USE OF BETA-BLOCKERS IN PRIMARY PREVENTION
    ROSENMAN, RH
    ACTIVITAS NERVOSA SUPERIOR, 1982, : 476 - 486
  • [47] Beta-blockers: which is the target? dose or heart rate?
    Gomes, F.
    Casal Moura, M.
    Carvalho, M.
    Silva, F.
    Laszczynska, O.
    Araujo, J. P.
    Alvelos, M.
    Pimenta, J.
    Azevedo, A.
    Bettencourt, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S94 - S94
  • [48] Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine
    Kitai T.
    Tang W.H.W.
    Current Treatment Options in Cardiovascular Medicine, 2016, 18 (2) : 1 - 15
  • [49] INTERACTIONS OF VASODILATORS WITH CALCIUM ENTRY-BLOCKERS AND BETA-BLOCKERS IN PATIENTS WITH CORONARY HEART-DISEASE
    STAUCH, M
    HAERER, W
    HENZE, E
    HERMANN, T
    KOHLER, J
    KRESS, P
    ADAM, WE
    ZEITSCHRIFT FUR KARDIOLOGIE, 1986, 75 : 106 - 111
  • [50] Use of beta-blockers in COPD patients with heart-disease. BBEPOC study
    Sobradillo, Patricia
    Fuster, Antonia
    Jorge Marcos, Pedro
    Ortega, Angel
    Gonzalez, Cruz
    Aburto, Myriam
    Luis Rodriguez, Juan
    Alcazar, Bernardino
    Calle, Myriam
    Puente, Luis
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42